In clinical trials, treating HCC patients with tamoxifen, which binds Estrogen Receptor α and blocks the effect of estrogen, resulted in a dose-dependent detrimental response with significantly fewer patients surviving for three months at higher doses [7]. The gene discussed is ESR1; the disease is hepatocellular carcinoma.